menu search

RDUS / Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer

Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer
The Menarini Group and Radius Health Inc's (NASDAQ: RDUS) data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology. The company says that elacestrant is the first oral. Read More
Posted: May 20 2022, 09:50
Author Name: Benzinga
Views: 111373

RDUS News  

Radius Recycling: Holding After The Rebrand

By Seeking Alpha
October 18, 2023

Radius Recycling: Holding After The Rebrand

Radius Recycling has experienced management and a strong balance sheet, but there are risks related to commodity prices, the strength of the dollar, a more_horizontal

Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer

By Benzinga
May 20, 2022

Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer

The Menarini Group and Radius Health Inc's (NASDAQ: RDUS) data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or meta more_horizontal

Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet

By Zacks Investment Research
March 1, 2022

Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet

The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is more_horizontal

Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet

By Zacks Investment Research
March 1, 2022

Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet

The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is more_horizontal

Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet

By Zacks Investment Research
March 1, 2022

Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet

The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is more_horizontal

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

By Zacks Investment Research
February 25, 2022

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing. more_horizontal

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

By Zacks Investment Research
February 25, 2022

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing. more_horizontal

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

By Zacks Investment Research
February 25, 2022

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing. more_horizontal


Search within

Pages Search Results: